

Remdesivir Infusion Orders (For COVID-19 Only)

Last Name:			
First Name (Preferred Name):			
Encounter number:	NH Number:	Chart Created: Yes/ No	
Date of Birth:	Gender:	Age:	Encounter Type:
Responsibility for Payment:		PHN:	
Primary Care Physician/Attending Physician:			
PATIENT LABEL			

Allergies: <input type="checkbox"/> None Known <input type="checkbox"/> Unable to Obtain List with Reactions: _____	Weight: _____ kg Height: _____ cm
---	--

*Note: follow infection control procedures for COVID-19 in all settings.
Please fax completed orders to pharmacy*

- CONSULT:** Refer to NH Firstline (app.firstline.org) for step-by-step eligibility guide for mild to moderate COVID-19 patients. For pregnant patients contact the reproductive ID specialist on-call at BC Women's Hospital: 604-875-2161.
- INCLUSION CRITERIA:** for patients unable to receive **nirmatrelvir-ritonavir** (Paxlovid), **remdesivir** may be considered in confirmed, mildly-ill COVID-19 patients (e.g. no supplemental oxygen), 18 years or older who are:
 - outpatients or hospitalized for non-COVID-19 related reasons (e.g. medical/surgical indications)
 - within 7 days of symptom onset
 - ***AND*** one of the following:
 - inadequate immune response to COVID-19 vaccine or high-risk conditions regardless of vaccine status (see page 2)
 - unimmunized and either 50 years or older or have three or more chronic conditions listed below
 - partially immunized and 50 years or older with three or more chronic conditions listed below
 - partially immunized and 70 years or older with one or more chronic conditions listed below
 - self-identify as Indigenous (e.g. First Nations [including status and non-status], Inuit, or Métis)

Chronic conditions that increase risk for developing severe COVID-19 related complications:

<input type="checkbox"/> hypertension/heart disease	<input type="checkbox"/> stroke
<input type="checkbox"/> chronic kidney disease	<input type="checkbox"/> neurological conditions
<input type="checkbox"/> COPD	<input type="checkbox"/> obesity (BMI greater than 30)
<input type="checkbox"/> diabetes	<input type="checkbox"/> smoking
- EXCLUSION CRITERIA**
Do NOT use **remdesivir** if any of the following:
 - previous hospitalization due to COVID-19
 - received previous outpatient treatment for COVID-19
 - symptoms consistent with severe COVID-19 defined by shortness of breath at rest or respiratory distress and requiring supplemental oxygen
 - presenting greater than 7 days from symptom onset or life expectancy of less than 7 days
 - ALT or AST greater than 3 times upper limit of normal
 - increased ALT or AST with other signs of liver inflammation, including elevation of bilirubin, alkaline phosphatase or INR
- LABORATORY**
Obtain baseline lab work if not done within last 6 months:
 - serum creatinine
 - ALT, AST, Alk phos, Total BILI, INR
- MONITORING**
 - *Initial:* temp, BP, HR, RR and SpO₂ prior to infusion then q1h until end of infusion
- MEDICATIONS**
 - remdesivir** 200 mg IV x 1 dose on day 1 ***THEN***
remdesivir 100 mg IV q24h x 2 days
 - If eGFR less than 30 mL/min:
 - remdesivir** 200 mg IV x 1 dose on day 1 ***THEN***
remdesivir 100 mg IV x 1 dose in 48 hours (may extend to 72 hours to coincide with hemodialysis run)

Prescriber signature: _____ **College ID:** _____ **Date:** _____ **Time:** _____



Remdesivir Infusion Orders
(For COVID-19 Only)

Last Name:			
First Name (Preferred Name):			
Encounter number:	NH Number:	Chart Created: Yes/ No	
Date of Birth:	Gender:	Age:	Encounter Type:
Responsibility for Payment:		PHN:	
Primary Care Physician/Attending Physician:			
PATIENT LABEL			

Patients who may have had an inadequate response to vaccination despite full vaccination for COVID-19 (any of the following):

- active treatment for solid tumor or hematological malignancies
- having received a solid organ transplant and treated with immunosuppression
- receiving CAR-T cell therapy or hematopoietic stem cell transplant in the last 2 years
- having a moderate to severe primary immunodeficiency
- having advanced untreated HIV or AIDS
- active receipt of anti-B cell therapies (e.g. **riTUXimab**, **ocrelizumab**, **obinutuzumab**), high-dose systemic steroids (= 20 mg **prednisone** equivalent daily for at least 14 days), alkylating agents (e.g. **cyclophosphamide**, **CISplatin**), antimetabolites (e.g. **methotrexate**, **fluorouracil**) or anti-TNF agents (e.g. **inFLIXimab**, **adalimumab**)

High-risk conditions regardless of vaccine status:

- 70 years or older with three or more chronic conditions (e.g. obesity, diabetes, heart failure stroke, neurological conditions)
- cystic fibrosis, insulin-dependent diabetes, severe asthma or COPD, blood disorders (e.g. sickle cell, thalassemia), rare metabolic disorders (e.g. urea cycle defects), splenectomy, pregnant with serious heart disease, significant development disorders (e.g. Cerebral Palsy), or neurological/other conditions causing significant muscle weakness around lungs